Money

Analyst Upgrades Restaurant Brands International Stock Following Investor Day

Vicki Robin
learn more

Bitcoin Nears $70,000 Amidst Geopolitical Tensions: An In-Depth Analysis

Bola Sokunbi

Sealed Air Corporation to Transition to Private Ownership in $10.3 Billion Acquisition

Dave Ramsey

Supreme Court Tariff Ruling: A New Era of Uncertainty for Small Businesses

Vicki Robin

The Golden Journey: A Century of Gold's Value Transformation

Natalie Pace

Maximize Your Tax Refund: Four Key Strategies Before April 15

Mr. Money Mustache

Carnival Corporation Stock Plunges Amid Middle East Tensions

Chika Uwazie

Staar Surgical's Upcoming Earnings: A Financial Insight

Staar Surgical (NASDAQ: STAA) is set to release its quarterly earnings report on March 3, 2026. Analysts predict an earnings per share (EPS) of $0.11. The market will closely watch the company's performance, especially its revenue growth, net margin, and return on assets, as these indicators highlight its financial health and operational efficiency. The company's smaller market capitalization and robust debt management strategy position it uniquely within the healthcare sector.

Chika Uwazie

Hyster-Yale's Financial Performance and Future Outlook

Hyster-Yale (NYSE: HY) is set to announce its quarterly earnings on March 3, 2026. Analysts predict an EPS of $-1.22. Investors are keen to see if the company surpasses these estimates and offers positive guidance for the upcoming quarter. Previous earnings reports show mixed results, with a notable share price drop after a miss last quarter. The company's stock has seen a 13.77% decline over the past 52 weeks, suggesting a bearish sentiment among long-term shareholders.

Natalie Pace

Marqeta's Performance: A Detailed Look at Q4 and Full-Year 2025 Results

Marqeta, a financial technology firm, recently announced its fourth-quarter and full-year 2025 financial outcomes. Despite a reduced price target from Morgan Stanley, the company demonstrated considerable growth in processing volume, net revenue, and gross profit. This report explores the figures and analyst perspectives, positioning Marqeta as a company with significant operational advancements and future potential.

Dave Ramsey

Wells Fargo Highlights AMP-007 as a Key Driver for Amphastar Pharmaceuticals' Future Growth

Wells Fargo recently reiterated its 'Overweight' rating on Amphastar Pharmaceuticals (AMPH) despite lowering its price target. The firm emphasized AMP-007's critical role in driving mid-to-high single-digit revenue growth. This outlook comes as the FDA approved AMPH's generic Ipratropium Bromide HFA Inhalation Aerosol, granting the company 180 days of market exclusivity and positioning it for significant expansion in the respiratory medication sector.

Chika Uwazie

EVgo's Upcoming Earnings Report: Investor Outlook

EVgo is set to release its quarterly earnings on March 3, 2026. Analysts predict an EPS of $-0.14. Investors are keenly awaiting the announcement, hoping for better-than-expected results and optimistic future guidance. Historically, positive earnings have not always led to immediate stock price increases, as market reactions are often more influenced by forward-looking statements.

Mr. Money Mustache

H.C. Wainwright Reaffirms Buy Rating for Armata Pharmaceuticals (ARMP) Following FDA's QIDP Designation

H.C. Wainwright has reiterated its "Buy" recommendation for Armata Pharmaceuticals (ARMP), boosting its price target from $9.00 to $15.00. This adjustment comes after the FDA granted Qualified Infectious Disease Product (QIDP) status to AP-SA02, Armata's multi-phage candidate for intravenous Staphylococcus aureus. The company is preparing to initiate a Phase 3 superiority trial for AP-SA02 in the latter half of 2026, targeting complex bloodstream infections caused by S. aureus.

Dave Ramsey

Goldman Sachs Raises Price Target for MoonLake Immunotherapeutics (MLTX) Despite Approval Concerns

Goldman Sachs has increased its price target for MoonLake Immunotherapeutics (MLTX) to $11 from $10, while maintaining a Sell rating. This adjustment follows the company's Q4 and full-year results, with operations funded into late 2027. Despite positive pipeline updates for sonelokimab in axial spondyloarthritis, Goldman Sachs remains skeptical about its regulatory approval prospects.

Natalie Pace

HealthStream Navigates AI Challenges, Delivers Strong Q4 Performance

HealthStream, Inc. (HSTM) has been recognized by Wall Street analysts as a promising small-cap stock. Despite market concerns about AI's impact on software companies, Canaccord Genuity reaffirmed HSTM's solid position after its impressive Q4 2025 results. The company reported record Q4 revenue of $79.7 million and significant growth in non-GAAP operating income and adjusted EBITDA, showcasing resilience and strategic acquisitions. HSTM, a leader in healthcare workforce solutions, is well-equipped to manage evolving industry dynamics.

Bola Sokunbi